

DAFTAR PUSTAKA

- Acunzo, M., Romano, G., Wernicke, D., & Croce, C. M. (2015). MicroRNA and cancer – A brief overview. *Advances in Biological Regulation*, *57*, 1–9. <https://doi.org/10.1016/j.jbior.2014.09.013>
- Agarwal, V., Bell, G. W., Nam, J.-W., & Bartel, D. P. (2015). Predicting effective microRNA target sites in mammalian mRNAs. *eLife*, *4*, e05005. <https://doi.org/10.7554/eLife.05005>
- Alshehade, S. A., Almoustafa, H. A., Alshawsh, M. A., & Chik, Z. (2024). Flow cytometry-based quantitative analysis of cellular protein expression in apoptosis subpopulations: A protocol. *Heliyon*, *10*(13), e33665. <https://doi.org/10.1016/j.heliyon.2024.e33665>
- American Type Culture Collection. (2024). *MDA-MB-231—HTB-26* | ATCC. <https://www.atcc.org/products/htb-26>
- Aoki, K., Satoi, S., Harada, S., Uchida, S., Iwasa, Y., & Ikenouchi, J. (2020). Coordinated changes in cell membrane and cytoplasm during maturation of apoptotic bleb. *Molecular Biology of the Cell*, *31*(8), 833–844. <https://doi.org/10.1091/mbc.E19-12-0691>
- Bjørklund, G., Rajib, S. A., Saffoon, N., Pen, J. J., & Chirumbolo, S. (2019). Insights on Melatonin as an Active Pharmacological Molecule in Cancer Prevention: What’s New? *Current Medicinal Chemistry*, *26*(34), 6304–6320. <https://doi.org/10.2174/0929867325666180501094850>
- Bonafede, R., Brandi, J., Manfredi, M., Scambi, I., Schiaffino, L., Merigo, F., Turano, E., Bonetti, B., Marengo, E., Cecconi, D., & Mariotti, R. (2019). The Anti-Apoptotic Effect of ASC-Exosomes in an In Vitro ALS Model and Their Proteomic Analysis. *Cells*, *8*(9), Article 9. <https://doi.org/10.3390/cells8091087>
- Boyd, V., Cholewa, O. M., & Papas, K. K. (2008). Limitations in the Use of Fluorescein Diacetate/Propidium Iodide (FDA/PI) and Cell Permeable Nucleic Acid Stains for Viability Measurements of Isolated Islets of Langerhans. *Current Trends in Biotechnology and Pharmacy*, *2*(2), 66–84.
- Buranaamnuay, K. (2021). The MTT assay application to measure the viability of spermatozoa: A variety of the assay protocols. *Open Veterinary Journal*, *11*(2), 251–269. <https://doi.org/10.5455/OVJ.2021.v11.i2.9>
- Byvaltsev, V. A., Bardanova, L. A., Onaka, N. R., Polkin, R. A., Ochkal, S. V., Shepelev, V. V., Aliyev, M. A., & Potapov, A. A. (2019). Acridine Orange: A Review of Novel Applications for Surgical Cancer Imaging and Therapy. *Frontiers in Oncology*, *9*, 925. <https://doi.org/10.3389/fonc.2019.00925>
- Catitti, G., De Fabritiis, S., Brocco, D., Simeone, P., De Bellis, D., Vespa, S., Veschi, S., De Lellis, L., Tinari, N., Verginelli, F., Marchisio, M., Cama, A., Patrino, A., & Lanuti, P. (2023). Flow Cytometry Detection of Anthracycline-Treated Breast Cancer Cells: An Optimized Protocol.

- Current Issues in Molecular Biology*, 45(1), Article 1.
<https://doi.org/10.3390/cimb45010013>
- Comfort, N., Bloomquist, T. R., Shephard, A. P., Petty, C. R., Cunningham, A., Hauptman, M., Phipatanakul, W., & Baccarelli, A. (2021). Isolation and characterization of extracellular vesicles in saliva of children with asthma. *Extracellular Vesicles and Circulating Nucleic Acids*, 2(1), 29–48.
<https://doi.org/10.20517/evcna.2020.09>
- Cossarizza, A., Chang, H.-D., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreato, F., Annunziato, F., Arranz, E., Bacher, P., Bari, S., Barnaba, V., Barros-Martins, J., Baumjohann, D., Beccaria, C. G., Bernardo, D., Boardman, D. A., Borger, J., ... Yang, J. (2021). Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). *European Journal of Immunology*, 51(12), 2708–3145.
<https://doi.org/10.1002/eji.202170126>
- Deng, Y. W., Hao, W. J., Li, Y. W., Li, Y. X., Zhao, B. C., & Lu, D. (2018). Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 *In Vivo*. *Journal of Breast Cancer*, 21(3), 251. <https://doi.org/10.4048/jbc.2018.21.e40>
- El Gazzar, W. B., Albakri, K. A., Hasan, H., Badr, A. M., Farag, A. A., & Saleh, O. M. (2023). Poly(ADP-ribose) polymerase inhibitors in the treatment landscape of triple-negative breast cancer (TNBC). *Journal of Oncology Pharmacy Practice*, 29(6), 1467–1479.
<https://doi.org/10.1177/10781552231188903>
- Fernandez-Piñeiro, I., Badiola, I., & Sanchez, A. (2017). Nanocarriers for microRNA delivery in cancer medicine. *Biotechnology Advances*, 35(3), 350–360. <https://doi.org/10.1016/j.biotechadv.2017.03.002>
- Ferrari, P., Scatena, C., Ghilli, M., Bargagna, I., Lorenzini, G., & Nicolini, A. (2022). Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. *International Journal of Molecular Sciences*, 23(3), Article 3. <https://doi.org/10.3390/ijms23031665>
- Gao, Q., Feng, J., Liu, W., Wen, C., Wu, Y., Liao, Q., Zou, L., Sui, X., Xie, T., Zhang, J., & Hu, Y. (2022). Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment. *Advanced Drug Delivery Reviews*, 188, 114445. <https://doi.org/10.1016/j.addr.2022.114445>
- Ghasemi, M., Turnbull, T., Sebastian, S., & Kempson, I. (2021). The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. *International Journal of Molecular Sciences*, 22(23), 12827. <https://doi.org/10.3390/ijms222312827>
- Ghebeh, H., Al-Sayed, A., Eiada, R., Cabangon, L., Ajarim, D., Suleman, K., Tulbah, A., & Al-Tweigeri, T. (2021). Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-

- negative metastatic breast cancer. *Scientific Reports*, 11(1), 19154. <https://doi.org/10.1038/s41598-021-98113-6>
- Haryana, S. M., Oktriani, R., Faiha, D. K., Conara, F. C., Dafip, M., & Setiasari, D. W. (2025). miR-143-3p: A Critical Regulator of KRAS and HRAS with Potential for Targeted Therapies in Breast Cancer. *Trends in Sciences*, 22(7), Article 7. <https://doi.org/10.48048/tis.2025.9630>
- He, Y., Zhu, Q., Chen, M., Huang, Q., Wang, W., Li, Q., Huang, Y., & Di, W. (2016). The changing 50% inhibitory concentration (IC 50) of cisplatin: A pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer. *Oncotarget*, 7(43), 70803–70821. <https://doi.org/10.18632/oncotarget.12223>
- Hedley, B. D., & Keeney, M. (2013). Technical issues: Flow cytometry and rare event analysis. *International Journal of Laboratory Hematology*, 35(3), 344–350. <https://doi.org/10.1111/ijlh.12068>
- Ho, P. T. B., Clark, I. M., & Le, L. T. T. (2022). MicroRNA-Based Diagnosis and Therapy. *International Journal of Molecular Sciences*, 23(13), 7167. <https://doi.org/10.3390/ijms23137167>
- Hou, Y., Feng, H., Jiao, J., Qian, L., Sun, B., Chen, P., Li, Q., & Liang, Z. (2019). Mechanism of miR-143-3p inhibiting proliferation, migration and invasion of osteosarcoma cells by targeting MAPK7. *Artificial Cells, Nanomedicine, and Biotechnology*, 47(1), 2065–2071. <https://doi.org/10.1080/21691401.2019.1620252>
- Jahangiri, B., Khalaj-Kondori, M., Asadollahi, E., Purrafee Dizaj, L., & Sadeghizadeh, M. (2022). MSC-Derived exosomes suppress colorectal cancer cell proliferation and metastasis via miR-100/mTOR/miR-143 pathway. *International Journal of Pharmaceutics*, 627, 122214. <https://doi.org/10.1016/j.ijpharm.2022.122214>
- Karimi, L., Mansoori, B., shanebandi, D., Mohammadi, A., Aghapour, M., & Baradaran, B. (2017). Function of microRNA-143 in different signal pathways in cancer: New insights into cancer therapy. *Biomedicine & Pharmacotherapy*, 91, 121–131. <https://doi.org/10.1016/j.biopha.2017.04.060>
- Kashyap, D., Garg, V. K., & Goel, N. (2021). Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis. In *Advances in Protein Chemistry and Structural Biology* (Vol. 125, pp. 73–120). Elsevier. <https://doi.org/10.1016/bs.apcsb.2021.01.003>
- Kim, Y. S., Karisa, N., Jeon, W. Y., Lee, H., Kim, Y., & Ahn, J. (2019). High-level production of N-terminal pro-brain natriuretic peptide, as a calibrant of heart failure diagnosis, in Escherichia coli. *Applied Microbiology and Biotechnology*, 103(12), 4779–4788. <https://doi.org/10.1007/s00253-019-09826-8>
- Lai, J. J., Chau, Z. L., Chen, S., Hill, J. J., Korpany, K. V., Liang, N., Lin, L., Lin, Y., Liu, J. K., Liu, Y., Lunde, R., & Shen, W. (2022). Exosome Processing

- and Characterization Approaches for Research and Technology Development. *Advanced Science*, 9(15), 2103222. <https://doi.org/10.1002/advs.202103222>
- Laowichuwakonnukul, K., Soontornworajit, B., Arunpanichlert, J., & Rotkrua, P. (2025). Simultaneous targeted delivery of doxorubicin and KRAS suppression by a hybrid molecule containing miR-143 and AS1411 aptamer. *Scientific Reports*, 15(1), 10590. <https://doi.org/10.1038/s41598-025-94159-y>
- Lee, S. H., & Jun, B.-H. (2019). Silver nanoparticles: Synthesis and application for nanomedicine. *International Journal of Molecular Sciences*, 20(4), 865.
- Li, Y., Zhao, Y., Gong, C., Xie, Y., Hu, X., Zhang, J., Wang, L., Zhang, S., Cao, J., & Tao, Z. (2019). Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer. *Scientific Reports*, 9(1), 3563.
- Liu, H., Wang, H., Liu, H., & Chen, Y. (2015). Effect of miR-143 on the apoptosis of osteosarcoma cells. *International Journal of Clinical and Experimental Pathology*, 8(11), 14241–14246.
- Lossi, L. (2022). The concept of intrinsic versus extrinsic apoptosis. *Biochemical Journal*, 479(3), 357–384. <https://doi.org/10.1042/BCJ20210854>
- Lv, W., Liu, Y., Li, S., Lv, L., Lu, H., & Xin, H. (2022). Advances of nano drug delivery system for the theranostics of ischemic stroke. *Journal of Nanobiotechnology*, 20(1), 248. <https://doi.org/10.1186/s12951-022-01450-5>
- Manjunath, M., & Choudhary, B. (2021). Triple-negative breast cancer: A run-through of features, classification and current therapies. *Oncology Letters*, 22(1), 1–21.
- Marinello, P. C., Panis, C., Silva, T. N. X., Binato, R., Abdelhay, E., Rodrigues, J. A., Mencalha, A. L., Lopes, N. M. D., Luiz, R. C., Cecchini, R., & Cecchini, A. L. (2019). Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes. *Scientific Reports*, 9(1), 5864. <https://doi.org/10.1038/s41598-019-42357-w>
- McKelvey, K. J., Powell, K. L., Ashton, A. W., Morris, J. M., & McCracken, S. A. (2015). Exosomes: Mechanisms of Uptake. *Journal of Circulating Biomarkers*, 4(1), Article 1. <https://doi.org/10.33393/jcb.2015.2057>
- Medina-Leyte, D. J., Domínguez-Pérez, M., Mercado, I., Villarreal-Molina, M. T., & Jacobo-Albavera, L. (2020). Use of Human Umbilical Vein Endothelial Cells (HUVEC) as a Model to Study Cardiovascular Disease: A Review. *Applied Sciences*, 10(3), Article 3. <https://doi.org/10.3390/app10030938>
- Nicoletto, R. E., & Ofner, C. M. (2022). Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. *Cancer*

- Chemotherapy and Pharmacology*, 89(3), 285–311.
<https://doi.org/10.1007/s00280-022-04400-y>
- Nilasari, F., & Haryana, S. M. (2023). *Efek Kombinasi mimic-hsa-miR-143-3p Terenkapsulasi Eksosom (ekso-miR) Terhadap Viabilitas, Migrasi, dan Proliferasi Triple Negative Breast Cancer* [Thesis, Universitas Gadjah Mada]. https://etd.repository.ugm.ac.id/home/detail_pencarian/224752
- Noficandra, H., & Haryana, S. M. (2024). *Pengaruh mimic-hsa-miR-143-3p Terenkapsulasi Eksosom terhadap Viabilitas dan Migrasi lini sel Hs578T : Validasi Eksperimental dan Prediksi Gen Target Secara In Silico* [Master Thesis, Universitas Gadjah Mada].
<https://etd.repository.ugm.ac.id/penelitian/detail/239040>
- Noh, J.-I., Mun, S.-K., Lim, E. H., Kim, H., Chang, D.-J., Hur, J.-S., & Yee, S.-T. (2021). Induction of Apoptosis in MDA-MB-231 Cells Treated with the Methanol Extract of Lichen *Physconia hokkaidensis*. *Journal of Fungi*, 7(3), 188. <https://doi.org/10.3390/jof7030188>
- Nuriliani, A., Conara, F. C., Oktavya, G., Hidayah, L. T. N., & Purwestri, Y. A. (2023). Ethanolic Extract of Black Rice ‘Sembada Hitam’ Bran Did not Show Cytotoxic Effect on HeLa Cell (Cervical Cancer Cell Line). *Bioma : Berkala Ilmiah Biologi*, 25(1), 49–59.
- Ouyang, M., Li, Y., Ye, S., Ma, J., Lu, L., Lv, W., Chang, G., Li, X., Li, Q., Wang, S., & Wang, W. (2014). MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer. *PLOS ONE*, 9(5), e96228. <https://doi.org/10.1371/journal.pone.0096228>
- Pilco-Ferreto, N., & Calaf, G. M. (2016). Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. *International Journal of Oncology*, 49(2), 753–762. <https://doi.org/10.3892/ijo.2016.3558>
- Purwanto, I., Heriyanto, D. S., Ghozali, A., Widodo, I., Dwiprahasto, I., Aryandono, T., & Haryana, S. M. (2020). Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer. *World Journal of Oncology*, 11(5), 216–222. <https://doi.org/10.14740/wjon1302>
- Qin, S.-Y., Cheng, Y.-J., Lei, Q., Zhang, A.-Q., & Zhang, X.-Z. (2018). Combinational strategy for high-performance cancer chemotherapy. *Biomaterials*, 171, 178–197.
<https://doi.org/10.1016/j.biomaterials.2018.04.027>
- Rui, D. (2004). *The influence of hypothermia on the proteins associated with apoptosis intrinsic pathway in the hippocampal CA1 area following global ischemia in gerbils*. <https://www.semanticscholar.org/paper/The-influence-of-hypothermia-on-the-proteins-with-Rui/1654e734665c3ce06575bcf7254df6df89532aab>
- Saikumar, P., Dong, Z., Mikhailov, V., Denton, M., Weinberg, J. M., & Venkatachalam, M. A. (1999). Apoptosis: Definition, mechanisms, and

- relevance to disease. *The American Journal of Medicine*, 107(5), 489–506. [https://doi.org/10.1016/S0002-9343\(99\)00259-4](https://doi.org/10.1016/S0002-9343(99)00259-4)
- Sanchez Calle, A., Kawamura, Y., Yamamoto, Y., Takeshita, F., & Ochiya, T. (2018). Emerging roles of long non-coding RNA in cancer. *Cancer Science*, 109(7), 2093–2100. <https://doi.org/10.1111/cas.13642>
- Sánchez-Díez, M., Romero-Jiménez, P., Alegría-Aravena, N., Gavira-O’Neill, C. E., Vicente-García, E., Quiroz-Troncoso, J., González-Martos, R., Ramírez-Castillejo, C., & Pastor, J. M. (2025). Assessment of Cell Viability in Drug Therapy: IC50 and Other New Time-Independent Indices for Evaluating Chemotherapy Efficacy. *Pharmaceutics*, 17(2), 247. <https://doi.org/10.3390/pharmaceutics17020247>
- Schroer, J., Warm, D., De Rosa, F., Luhmann, H. J., & Sinning, A. (2023). Activity-dependent regulation of the BAX/BCL-2 pathway protects cortical neurons from apoptotic death during early development. *Cellular and Molecular Life Sciences*, 80(6), 1–20. <https://doi.org/10.1007/s00018-023-04824-6>
- Sebaugh, J. L. (2011). Guidelines for accurate EC50/IC50 estimation. *Pharmaceutical Statistics*, 10(2), 128–134. <https://doi.org/10.1002/pst.426>
- Sen, S., Xavier, J., Kumar, N., Ahmad, M. Z., & Ranjan, O. P. (2023). Exosomes as natural nanocarrier-based drug delivery system: Recent insights and future perspectives. *3 Biotech*, 13(3), 1–25. <https://doi.org/10.1007/s13205-023-03521-2>
- Takai, T., Tsujino, T., Yoshikawa, Y., Inamoto, T., Sugito, N., Kuranaga, Y., Heishima, K., Soga, T., Hayashi, K., Miyata, K., Kataoka, K., Azuma, H., & Akao, Y. (2019). Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo. *Molecular Therapy*, 27(5), 1017–1027. <https://doi.org/10.1016/j.ymthe.2019.03.004>
- Tang, J., Pan, H., Wang, W., Qi, C., Gu, C., Shang, A., & Zhu, J. (2021). MiR-495-3p and miR-143-3p co-target CDK1 to inhibit the development of cervical cancer. *Clinical and Translational Oncology*, 23(11), 2323–2334. <https://doi.org/10.1007/s12094-021-02687-6>
- Tang, Z., Hu, S., Wu, Z., & He, M. (2023). Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3. *Molecular Medicine*, 29(1), 96. <https://doi.org/10.1186/s10020-023-00695-6>
- Tenchov, R., Sasso, J. M., Wang, X., Liaw, W.-S., Chen, C.-A., & Zhou, Q. A. (2022). Exosomes—Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics. *ACS Nano*, 16(11), 17802–17846. <https://doi.org/10.1021/acsnano.2c08774>
- Tian, H., Ma, D., Tan, X., Yan, W., Wu, X., He, C., Zhong, L., Zhang, Y., Yu, B., Zhang, Y., & Qi, X. (2021). Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A

- Narrative Review. *Frontiers in Pharmacology*, 12.
<https://doi.org/10.3389/fphar.2021.770663>
- Verschoor, C. P., Lelic, A., Bramson, J. L., & Bowdish, D. M. E. (2015). An Introduction to Automated Flow Cytometry Gating Tools and Their Implementation. *Frontiers in Immunology*, 6.
<https://doi.org/10.3389/fimmu.2015.00380>
- Welsh, J. (2013). Animal Models for Studying Prevention and Treatment of Breast Cancer. In *Animal Models for the Study of Human Disease* (pp. 997–1018). Elsevier. <https://doi.org/10.1016/B978-0-12-415894-8.00040-3>
- Wilczynska, A., & Bushell, M. (2015). The complexity of miRNA-mediated repression. *Cell Death & Differentiation*, 22(1), 22–33.
<https://doi.org/10.1038/cdd.2014.112>
- Xi, Y., Li, T., Xi, Y., Zeng, X., Miao, Y., Guo, R., Zhang, M., & Li, B. (2022). Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer. *Cancer Cell International*, 22(1), 271. <https://doi.org/10.1186/s12935-022-02681-0>
- Xia, C., Yang, Y., Kong, F., Kong, Q., & Shan, C. (2018). MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7. *Biochimie*, 147, 98–104.
- Xia, M., Zu, X., Chen, Z., Wen, G., & Zhong, J. (2021). Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance. *Cancer Letters*, 523, 100–110. <https://doi.org/10.1016/j.canlet.2021.09.038>
- Xie, F., Li, C., Zhang, X., Peng, W., & Wen, T. (2019). MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS. *Biomedicine & Pharmacotherapy*, 119, 109424.
- Xu, J., & Jia, Y. (2025). miR-361-5p regulates SLC25A24 to maintain mitochondrial function and alleviate granulosa cell dysfunction in diminished ovarian reserve. *Journal of Assisted Reproduction and Genetics*, 42(3), 923–936. <https://doi.org/10.1007/s10815-024-03349-6>
- Yakubovich, E. I., Polischouk, A. G., & Evtushenko, V. I. (2022). Principles and Problems of Exosome Isolation from Biological Fluids. *Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology*, 16(2), 115–126. <https://doi.org/10.1134/S1990747822030096>
- Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. *Frontiers in Molecular Biosciences*, 7, 193.
- YiRan Li, V., Rosas, N., Fleischer, S., Vunjak-Novakovic, G., & Cheng, K. (2025). MicroRNAs won the Nobel Prize. Now, can extracellular vesicles help them become drugs? *Extracellular Vesicle*, 5, 100080.
<https://doi.org/10.1016/j.vesic.2025.100080>

- Yoshikawa, Y., Taniguchi, K., Tsujino, T., Heishima, K., Inamoto, T., Takai, T., Minami, K., Azuma, H., Miyata, K., Hayashi, K., Kataoka, K., & Akao, Y. (2019). Anti-cancer Effects of a Chemically Modified miR-143 on Bladder Cancer by Either Systemic or Intravesical Treatment. *Molecular Therapy - Methods & Clinical Development*, 13, 290–302. <https://doi.org/10.1016/j.omtm.2019.02.005>
- Yulian, E. D., & Fachriza, I. (2024). Five-year survival of triple-negative breast cancer and the associated clinicopathological factors: A study in an Indonesian tertiary hospital. *Medical Journal of Indonesia*, 32(4), 230–237. <https://doi.org/10.13181/mji.oa.247161>
- Zaer, S. J., Aghamaali, M., Najafi, S., Hosseini, S. S., Amini, M., Doustvandi, M. A., Mozammel, N., Baradaran, B., & Mokhtarzadeh, A. A. (2025). MicroRNA-143 overexpression enhances the chemosensitivity of A172 glioblastoma cells to carmustine. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 398(1), 533–542. <https://doi.org/10.1007/s00210-024-03287-1>
- Zhao, Y., Tu, M.-J., Yu, Y.-F., Wang, W.-P., Chen, Q.-X., Qiu, J.-X., Yu, A.-X., & Yu, A.-M. (2015). Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth. *Biochemical Pharmacology*, 98(4), 602–613. <https://doi.org/10.1016/j.bcp.2015.10.015>
- Zhou, L. L., Dong, J. L., Huang, G., Sun, Z. L., & Wu, J. (2017). MicroRNA-143 inhibits cell growth by targeting ERK5 and MAP3K7 in breast cancer. *Brazilian Journal of Medical and Biological Research*, 50, e5891. <https://doi.org/10.1590/1414-431X20175891>